Publication | Closed Access

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

OncologyMedicineMetronomic TherapyBronchial NeoplasmPharmacotherapyCancer TreatmentPharmacologyLung Cancer